SG11202108552QA - Compounds, compositions and methods - Google Patents
Compounds, compositions and methodsInfo
- Publication number
- SG11202108552QA SG11202108552QA SG11202108552QA SG11202108552QA SG11202108552QA SG 11202108552Q A SG11202108552Q A SG 11202108552QA SG 11202108552Q A SG11202108552Q A SG 11202108552QA SG 11202108552Q A SG11202108552Q A SG 11202108552QA SG 11202108552Q A SG11202108552Q A SG 11202108552QA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- compounds
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962805263P | 2019-02-13 | 2019-02-13 | |
US201962877232P | 2019-07-22 | 2019-07-22 | |
PCT/US2020/018007 WO2020168011A1 (en) | 2019-02-13 | 2020-02-12 | Compounds, compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202108552QA true SG11202108552QA (en) | 2021-09-29 |
Family
ID=72043948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202108552QA SG11202108552QA (en) | 2019-02-13 | 2020-02-12 | Compounds, compositions and methods |
Country Status (18)
Country | Link |
---|---|
US (2) | US11306077B2 (en) |
EP (1) | EP3923935A4 (en) |
JP (1) | JP2022520236A (en) |
KR (1) | KR20210126036A (en) |
CN (1) | CN113518618A (en) |
AU (1) | AU2020223228A1 (en) |
BR (1) | BR112021015639A2 (en) |
CA (1) | CA3129609A1 (en) |
CL (1) | CL2021002104A1 (en) |
CO (1) | CO2021010490A2 (en) |
CR (1) | CR20210426A (en) |
IL (1) | IL285302A (en) |
MA (1) | MA54953A (en) |
MX (1) | MX2021009669A (en) |
PE (1) | PE20212023A1 (en) |
SG (1) | SG11202108552QA (en) |
TW (1) | TW202045164A (en) |
WO (1) | WO2020168011A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018313850B2 (en) | 2017-08-09 | 2022-12-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
CA3085132A1 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
BR112020023115A2 (en) | 2018-06-05 | 2021-02-02 | Praxis Biotech LLC | integrated voltage response pathway inhibitors |
SG11202108552QA (en) | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
EP3982965A4 (en) | 2019-06-12 | 2023-01-25 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
EP4117780A1 (en) | 2020-03-11 | 2023-01-18 | Evotec International GmbH | Modulators of the integrated stress response pathway |
AU2021363616A1 (en) | 2020-10-22 | 2023-06-22 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
KR20230110511A (en) | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | Modulators of the integrated stress response pathway |
JP2023546225A (en) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Modulators of integrated stress response pathways |
MX2023007066A (en) * | 2020-12-18 | 2023-07-25 | Denali Therapeutics Inc | Solid forms of a compound. |
WO2024032501A1 (en) * | 2022-08-08 | 2024-02-15 | 深圳众格生物科技有限公司 | Compound, pharmaceutical composition comprising same, and use thereof |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
EP1045693B1 (en) | 1998-10-16 | 2004-06-30 | Daiichi Suntory Pharma Co., Ltd. | Aminophenoxyacetic acid derivatives as neuroprotectants |
AR024077A1 (en) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | ANTIBACTERIAL COMPOUNDS |
WO2001081317A1 (en) * | 2000-04-26 | 2001-11-01 | Gliatech, Inc. | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
WO2002080928A1 (en) * | 2001-04-03 | 2002-10-17 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1 |
RU2440991C2 (en) | 2004-09-02 | 2012-01-27 | Вертекс Фармасьютикалз Инкорпорейтед | Quinazoline effective as ion channel modulators |
RU2007147413A (en) | 2005-05-24 | 2009-06-27 | Астразенека Аб (Se) | AMINOPIPERIDINCHINOLINS AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY |
SG170767A1 (en) * | 2005-12-23 | 2011-05-30 | Zealand Pharma As | Modified lysine-mimetic compounds |
JP2010507586A (en) | 2006-10-20 | 2010-03-11 | アレテ セラピューティクス, インコーポレイテッド | Soluble epoxide hydrolase inhibitor |
ATE520687T1 (en) | 2007-06-15 | 2011-09-15 | Actelion Pharmaceuticals Ltd | 3-AMINO-6-(1-AMINO-ETHYL)-TETRAHYDROPYRANDERIVA E |
SI2376497T1 (en) | 2008-12-12 | 2014-01-31 | Actelion Pharmaceuticals Ltd. | 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives |
US9421211B2 (en) | 2009-05-28 | 2016-08-23 | President And Fellows Of Harvard College | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation |
HUE031048T2 (en) | 2009-06-17 | 2017-06-28 | Vertex Pharma | Inhibitors of influenza viruses replication |
AR084457A1 (en) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | BICYCLE DERIVATIVES [3,2,1] OCTILAMIDE |
WO2012113774A1 (en) | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
TWI494312B (en) | 2011-03-10 | 2015-08-01 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivatives |
CN106946795B (en) | 2011-04-22 | 2020-06-02 | 西格诺药品有限公司 | Substituted diaminocarboxamides and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith |
JP2015512873A (en) * | 2012-02-14 | 2015-04-30 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | Nematicidal cis (hetero) arylcyclopropylcarboxamide derivatives |
EP2905279A4 (en) | 2012-10-02 | 2016-04-20 | Sumitomo Dainippon Pharma Co Ltd | Imidazole derivative |
EP2970104B1 (en) | 2013-03-14 | 2019-04-24 | Zeno Royalties & Milestones, LLC | Bicyclic analgesic compounds |
CA2904794C (en) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US20160318856A1 (en) | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
KR20170003553A (en) | 2014-04-04 | 2017-01-09 | 사이로스 파마수티컬스, 인크. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
JP6833677B2 (en) | 2014-09-17 | 2021-02-24 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Bicyclic compound |
KR20230158647A (en) | 2014-11-20 | 2023-11-20 | 메르크 파텐트 게엠베하 | Heteroaryl compounds as irak inhibitors and uses thereof |
JP6612874B2 (en) | 2014-12-16 | 2019-11-27 | アクソファント サイエンシーズ ゲーエムベーハー | Geminal-substituted quinuclidineamide compounds as agonists of α7-nicotinic acetylcholine receptors |
BR112017018305A2 (en) | 2015-02-25 | 2018-04-17 | Univ Rice William M | deacetoxytubulisine h and analogs thereof |
GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
US20180148418A1 (en) | 2015-05-05 | 2018-05-31 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
TW201718557A (en) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | Pyrazolyl substituted tetrahydropyranylsulfones |
TW201808903A (en) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
TW201808888A (en) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
TW201808914A (en) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
TWI763668B (en) * | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | Modulators of the integrated stress pathway |
CA3026983A1 (en) * | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
WO2017212425A1 (en) | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
JP7006960B2 (en) | 2016-07-06 | 2022-01-24 | アクイスト エルエルシー | Compounds to reduce uric acid levels and their use |
JOP20190072A1 (en) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors |
JP7128816B2 (en) | 2016-12-08 | 2022-08-31 | ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム | Bicyclo[1.1.1]pentane inhibitors of the double leucine zipper (DLK) kinase for the treatment of disease |
WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
BR112020000122A2 (en) * | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | derivatives of n- (3- (2- (4-chlorophenoxy) acetamido) bicyclo [1.1.1] pentan-1-yl) -2-cyclobutane-1-carboxamide and related compounds as inhibitors of atf4 for treatment against cancer and other diseases |
BR112020000086A2 (en) | 2017-07-03 | 2020-07-07 | Glaxosmithkline Intellectual Property Development Limited | 2- (4-chlorophenoxy) -n - ((1- (2- (4-chlorophenoxy) ethinazetidin-3-yl) methyl) acetamide derivatives and related compounds as inhibitors of atf4 for the treatment of cancer and other diseases |
AU2018313850B2 (en) | 2017-08-09 | 2022-12-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
SI3676297T1 (en) | 2017-09-01 | 2023-12-29 | Denali Therapeutics Inc. | Compounds, compositions and methods |
WO2019054430A1 (en) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | Amide compound having aromatic heterocycle |
UY37956A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
CA3080948A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
WO2019090074A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
UY37958A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
MX2020004537A (en) | 2017-11-02 | 2020-10-05 | Calico Life Sciences Llc | Modulators of the integrated stress pathway. |
IL274406B2 (en) | 2017-11-02 | 2024-04-01 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
UY37957A (en) | 2017-11-02 | 2019-05-31 | Abbvie Inc | INTEGRATED STRESS ROAD MODULATORS |
AU2018358160B2 (en) | 2017-11-02 | 2023-03-16 | Abbvie Inc. | Modulators of the integrated stress pathway |
US20210205277A1 (en) | 2017-11-02 | 2021-07-08 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
CA3085132A1 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
US20210130308A1 (en) | 2018-03-23 | 2021-05-06 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
JP2021529814A (en) | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Chemical compound |
WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
TWI771621B (en) | 2018-10-11 | 2022-07-21 | 美商嘉來克生命科學有限責任公司 | Prodrug modulators of the integrated stress pathway |
SG11202108552QA (en) * | 2019-02-13 | 2021-09-29 | Denali Therapeutics Inc | Compounds, compositions and methods |
EP3924341A4 (en) | 2019-02-13 | 2022-11-02 | Denali Therapeutics Inc. | Compounds, compositions and methods |
US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
CN114206848A (en) | 2019-04-30 | 2022-03-18 | 卡里科生命科学有限责任公司 | Substituted cycloalkyl compounds as modulators of integrated stress pathways |
CN114401952A (en) | 2019-04-30 | 2022-04-26 | 卡里科生命科学有限责任公司 | Substituted cycloalkyl compounds as modulators of integrated stress pathways |
MX2023007066A (en) | 2020-12-18 | 2023-07-25 | Denali Therapeutics Inc | Solid forms of a compound. |
-
2020
- 2020-02-12 SG SG11202108552QA patent/SG11202108552QA/en unknown
- 2020-02-12 BR BR112021015639-9A patent/BR112021015639A2/en unknown
- 2020-02-12 KR KR1020217027796A patent/KR20210126036A/en active Search and Examination
- 2020-02-12 PE PE2021001317A patent/PE20212023A1/en unknown
- 2020-02-12 CR CR20210426A patent/CR20210426A/en unknown
- 2020-02-12 MX MX2021009669A patent/MX2021009669A/en unknown
- 2020-02-12 JP JP2021547076A patent/JP2022520236A/en active Pending
- 2020-02-12 WO PCT/US2020/018007 patent/WO2020168011A1/en active Application Filing
- 2020-02-12 TW TW109104414A patent/TW202045164A/en unknown
- 2020-02-12 CA CA3129609A patent/CA3129609A1/en active Pending
- 2020-02-12 MA MA054953A patent/MA54953A/en unknown
- 2020-02-12 EP EP20755645.7A patent/EP3923935A4/en active Pending
- 2020-02-12 AU AU2020223228A patent/AU2020223228A1/en active Pending
- 2020-02-12 CN CN202080017506.7A patent/CN113518618A/en active Pending
-
2021
- 2021-05-28 US US17/334,587 patent/US11306077B2/en active Active
- 2021-08-02 IL IL285302A patent/IL285302A/en unknown
- 2021-08-10 CL CL2021002104A patent/CL2021002104A1/en unknown
- 2021-08-10 CO CONC2021/0010490A patent/CO2021010490A2/en unknown
-
2022
- 2022-03-23 US US17/702,718 patent/US11958840B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CR20210426A (en) | 2021-09-30 |
KR20210126036A (en) | 2021-10-19 |
EP3923935A1 (en) | 2021-12-22 |
MX2021009669A (en) | 2021-10-13 |
US20230114472A1 (en) | 2023-04-13 |
IL285302A (en) | 2021-09-30 |
JP2022520236A (en) | 2022-03-29 |
MA54953A (en) | 2021-12-22 |
CO2021010490A2 (en) | 2021-08-30 |
US20210292311A1 (en) | 2021-09-23 |
TW202045164A (en) | 2020-12-16 |
BR112021015639A2 (en) | 2021-10-05 |
US11958840B2 (en) | 2024-04-16 |
CL2021002104A1 (en) | 2022-04-08 |
AU2020223228A1 (en) | 2021-08-26 |
CA3129609A1 (en) | 2020-08-20 |
PE20212023A1 (en) | 2021-10-18 |
WO2020168011A1 (en) | 2020-08-20 |
US11306077B2 (en) | 2022-04-19 |
CN113518618A (en) | 2021-10-19 |
EP3923935A4 (en) | 2022-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285215A (en) | Immunomodulators, compositions and methods thereof | |
IL272089A (en) | Compounds, compositions and methods | |
IL285302A (en) | Compounds, compositions and methods | |
HUE062446T2 (en) | Compounds, compositions and methods | |
EP3924341A4 (en) | Compounds, compositions and methods | |
GB201903287D0 (en) | Composition | |
SG11202006994XA (en) | Antibacterial compounds, compositions thereof, and methods using same | |
IL287120A (en) | Compounds, compositions and methods | |
GB201913593D0 (en) | Composition | |
GB202017595D0 (en) | Compositions, and methods and uses relating thereto | |
GB2576614B (en) | Compositions, uses and methods | |
IL284800A (en) | Methods, uses & compositions | |
GB201804163D0 (en) | Uses, compositions and methods | |
GB201912061D0 (en) | Composition | |
IL270505B1 (en) | Compounds, compositions and methods | |
GB201916217D0 (en) | Composition | |
EP3807247A4 (en) | Photostabilizing compounds, compositions, and methods | |
EP3806814A4 (en) | Photostabilizing compounds, compositions, and methods | |
GB201911694D0 (en) | Composition | |
GB201911454D0 (en) | Composition | |
GB201907225D0 (en) | Composition | |
GB201903340D0 (en) | Composition | |
EP3806815A4 (en) | Photostabilizing compounds, compositions, and methods | |
EP3807275A4 (en) | Photostabilizing compounds, compositions, and methods | |
GB201916058D0 (en) | Composition |